Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
KINETA, INC. (PTI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/05/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "PRE-FUNDED COMMON STOCK PURCHASE WARRANT KINETA, INC. Warrant Shares: _______ Initial Exercise Date: October ___, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Kineta, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set fort...",
"COMMON STOCK PURCHASE WARRANT Kineta, Inc. Warrant Shares: _______ Initial Exercise Date: October ___, 2023 Issue Date: October ___, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _______, 2023 and on or prior to 5:00 p.m. on _____, 2028 but not thereafter, to subscribe for and purchase from Kineta, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings se...",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Kineta, Inc. Warrant Shares: _______ Initial Exercise Date: October 5, 2023 Issue Date: October 5, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October _____, 2023 and on or prior to 5:00 p.m. on October _____, 2028 but not thereafter, to subscribe for and purchase from Kineta, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is issued pursuant to that certain Engagement Agree...",
"Orrick, Herrington & Sutcliffe LLP 222 Berkeley St. Ste. 2000 Boston, MA 02116 +1-617-880-1800 orrick.com October 5, 2023 Kineta, Inc. 219 Terry Ave. N., Suite 300 Seattle, WA 98109 Re: Offering of Common Stock and Warrants",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of October 3, 2023, between Kineta, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares, the Pre-Funded Warrants and Pre-Funded Warrant Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Common Warrants and the Common Warrant Shares , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Compa...",
"Investor Contact:"
10/05/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors"
10/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level >90% VISTA Receptor Occupancy Observed in the 30 mg Dosing Cohort VISTA Blocking KVA12123 Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events Clinical Trial is Advancing to Higher Monotherapy Dose Levels and in Combination with Pembrolizumab Initial Monotherapy Clinical Efficacy Data Anticipated in Q4 2023"
08/16/2023 8-K Other Events  Interactive Data
08/11/2023 8-K Investor presentation
Docs: "0.5 0.4 0.1 0.3 0.2 0"
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/11/2023 8-K Quarterly results
Docs: "Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment from Merck Cash Runway into early 2025"
07/21/2023 8-K Quarterly results
07/05/2023 4 Dylla Scott J. (Director) has filed a Form 4 on KINETA, INC./DE
Txns: Granted 20,000 options to buy @ $2.58, valued at $51.6k
07/05/2023 4 Drapkin Kimberlee C (Director) has filed a Form 4 on KINETA, INC./DE
Txns: Granted 20,000 options to buy @ $2.58, valued at $51.6k
07/05/2023 3 Dylla Scott J. (Director) has filed a Form 3 on KINETA, INC./DE
07/05/2023 3 Drapkin Kimberlee C (Director) has filed a Form 3 on KINETA, INC./DE
07/03/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
06/29/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Kineta to Receive $5 Million Milestone Payment from Merck Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis"
06/16/2023 4 PHILIPS CRAIG W. (President) has filed a Form 4 on KINETA, INC./DE
Txns: Paid exercise price by delivering 12,666 shares @ $2.82, valued at $35.7k
Exercised 1,382 options to buy @ $0.14, valued at $193.5
06/16/2023 4 Kenny Pauline (General Counsel & Secretary) has filed a Form 4 on KINETA, INC./DE
Txns: Paid exercise price by delivering 858 shares @ $2.82, valued at $2.4k
06/16/2023 4 Iadonato Shawn (CEO) has filed a Form 4 on KINETA, INC./DE
Txns: Paid exercise price by delivering 7,439 shares @ $2.82, valued at $21k
Exercised 1,382 warrants @ $0.14, valued at $193.5
06/16/2023 4 Bartoszek Raymond J. (Director) has filed a Form 4 on KINETA, INC./DE
Txns: Exercised 60,018 warrants @ $0.14, valued at $8.4k
06/16/2023 4 Baker Keith (CFO) has filed a Form 4 on KINETA, INC./DE
Txns: Bought 5,000 shares @ $2.92, valued at $14.6k
06/13/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/09/2023 8-K Investor presentation
Docs: "0.5 0.4 0.1 0.3 0.2 0"
06/01/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/24/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Kineta set to join Russell Microcap® Index"
05/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Kineta to Present at Jefferies Healthcare Conference"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules"
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/21/2023 8-K Quarterly results
04/21/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy